ERBB2 and breast carcinoma: Several antibody–drug conjugates are also under development; ado–trastuzumab emtansine (Kadcyla)—where the cytotoxic agent is linked to trastuzumab through a thioether linker—is already approved and in use in several countries for multidrug-resistant HER2+ breast cancers [13].